Biotech Values

[rkrw]

You guys are way overthinking this. MNTA has more than enough money to spend on generic Copaxone and the spend required is probably a lot less than you think. And they have Novartis behind them. It's a non factor. I'd look for Teva to price just 5-10% below Sandoz should they receive approval.